This company has been acquired
ESSA Pharma (EPIX) Stock Overview
A clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
EPIX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ESSA Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$6.45 |
| 52 Week Low | US$0.18 |
| Beta | 1.53 |
| 1 Month Change | -1.85% |
| 3 Month Change | -88.23% |
| 1 Year Change | -96.77% |
| 3 Year Change | -89.73% |
| 5 Year Change | -97.01% |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth
Aug 21
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate
Feb 18ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans
Aug 16Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)
Jan 25We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely
Dec 15Shareholder Returns
| EPIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.4% | -0.8% | 0.3% |
| 1Y | -96.8% | 26.8% | 16.2% |
Return vs Industry: EPIX underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: EPIX underperformed the US Market which returned 17.8% over the past year.
Price Volatility
| EPIX volatility | |
|---|---|
| EPIX Average Weekly Movement | 25.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EPIX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EPIX's weekly volatility has increased from 17% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 35 | David Parkinson | www.essapharma.com |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc. Fundamentals Summary
| EPIX fundamental statistics | |
|---|---|
| Market cap | US$9.52m |
| Earnings (TTM) | -US$25.27m |
| Revenue (TTM) | n/a |
Is EPIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPIX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$25.27m |
| Earnings | -US$25.27m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did EPIX perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/10 02:26 |
| End of Day Share Price | 2025/10/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ESSA Pharma Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maurice Raycroft | Jefferies LLC |
| Soumit Roy | JonesTrading Institutional Services, LLC |
| Elemer Piros | Roth Capital Partners |